Mylan and Pfizer have entered an agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.   The new company will transform and accelerate each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets by bringing together the two businesses. Mylan brings a diverse portfolio across many geographies and key therapeutic areas, such as central nervous sys...